Literature DB >> 21563698

Clospore: a liquid medium for producing high titers of semi-purified spores of Clostridium difficile.

Justo Perez1, V Susan Springthorpe, Syed A Sattar.   

Abstract

Clostridium difficile continues to cause infections in healthcare and other settings. Its spores survive well indoors and require sporicidal chemicals for infection control. However, proper testing of disinfectants is impeded due to difficulties in obtaining viable spores of high enough quality and titers to meet current regulations for sporicidal claims. A new liquid medium (Clospore) has been developed, based on a systematic review of the compositions of 20 other available media. C. difficile spores grown in the new medium and treated with a mixture of lysozyme and trypsin yielded final suspensions with > 10(9) CFU/mL of viable spores, with a purity of > 91% as tested by spore-staining and phase-contrast microscopy. The spores showed a biological decay rate of about 0.1 log10/month when dried on metal disks and stored indoors (air temperature 23 +/- 2 degrees C; relative humidity 52.76 +/- 15.08%). Heating the purified spore suspensions to 70 degrees C for 10 min to inactivate any vegetative cells showed no spore activation or inactivation. The spores could be stored for at least 14 months either refrigerated (4 degrees C) or frozen (-20 or -80 degrees C) in 50% (v/v) ethanol with virtually no loss in viability. The resistance of the enzyme-treated spores to three levels of sodium hypochlorite (1000, 3000, and 5000 ppm), using a standardized quantitative carrier test, was almost identical to that of the spores concentrated by centrifugation alone. The described procedure has been successfully applied to four standard (ATCC) and six clinical strains of C. difficile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563698

Source DB:  PubMed          Journal:  J AOAC Int        ISSN: 1060-3271            Impact factor:   1.913


  41 in total

1.  Cwp22, a novel peptidoglycan cross-linking enzyme, plays pleiotropic roles in Clostridioides difficile.

Authors:  Duolong Zhu; Jessica Bullock; Yongqun He; Xingmin Sun
Journal:  Environ Microbiol       Date:  2019-06-28       Impact factor: 5.491

2.  Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291.

Authors:  Jenessa A Winston; Rajani Thanissery; Stephanie A Montgomery; Casey M Theriot
Journal:  J Vis Exp       Date:  2016-12-10       Impact factor: 1.355

3.  Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice.

Authors:  Andrew J McDermott; Charles R Frank; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Gut Microbes       Date:  2014-07-21

4.  Clostridium difficile-induced colitis in mice is independent of leukotrienes.

Authors:  Bruno C Trindade; Casey M Theriot; Jhansi L Leslie; Paul E Carlson; Ingrid L Bergin; Marc Peters-Golden; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2014-09-16       Impact factor: 3.331

5.  Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids.

Authors:  Rajani Thanissery; Jenessa A Winston; Casey M Theriot
Journal:  Anaerobe       Date:  2017-03-06       Impact factor: 3.331

6.  The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain.

Authors:  Keshan Zhang; Song Zhao; Yuankai Wang; Xuejun Zhu; Hong Shen; Yugen Chen; Xingmin Sun
Journal:  Anaerobe       Date:  2015-10-13       Impact factor: 3.331

7.  Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission.

Authors:  Scott R Curry; Carlene A Muto; Jessica L Schlackman; A William Pasculle; Kathleen A Shutt; Jane W Marsh; Lee H Harrison
Journal:  Clin Infect Dis       Date:  2013-07-23       Impact factor: 9.079

8.  Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.

Authors:  Yuanguo Wang; Shaohui Wang; Laurent Bouillaut; Chunhui Li; Zhibian Duan; Keshan Zhang; Xianghong Ju; Saul Tzipori; Abraham L Sonenshein; Xingmin Sun
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

9.  Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract.

Authors:  Mark J Koenigsknecht; Casey M Theriot; Ingrid L Bergin; Cassie A Schumacher; Patrick D Schloss; Vincent B Young
Journal:  Infect Immun       Date:  2014-12-22       Impact factor: 3.441

10.  A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift.

Authors:  Hyeun Bum Kim; Yuankai Wang; Xingmin Sun
Journal:  J Microbiol Biotechnol       Date:  2016-03       Impact factor: 2.351

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.